Literature DB >> 1658392

A minimal lentivirus Tat.

D Derse1, M Carvalho, R Carroll, B M Peterlin.   

Abstract

Transcriptional regulatory mechanisms found in lentiviruses employ RNA enhancer elements called trans-activation responsive (TAR) elements. These nascent RNA stem-loops are cis-acting targets of virally encoded Tat effectors. Interactions between Tat and TAR increase the processivity of transcription complexes and lead to efficient copying of viral genomes. To study essential elements of this trans activation, peptide motifs from Tats of two distantly related lentiviruses, equine infectious anemia virus (EIAV) and human immunodeficiency virus type 1 (HIV-1), were fused to the coat protein of bacteriophage R17 and tested on the long terminal repeat of EIAV, where TAR was replaced by the R17 operator, the target of the coat protein. This independent RNA-tethering mechanism mapped activation domains of Tats from HIV-1 and EIAV to 47 and 15 amino acids and RNA-binding domains to 10 and 26 amino acids, respectively. Thus, a minimal lentivirus Tat consists of 25 amino acids, of which 15 modify viral transcription and 10 bind to the target RNA stem-loop.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658392      PMCID: PMC250818     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  The HIV-1 Tat protein: an RNA sequence-specific processivity factor?

Authors:  B R Cullen
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

Review 2.  Human immunodeficiency virus as a prototypic complex retrovirus.

Authors:  B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

4.  Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat.

Authors:  M J Selby; E S Bain; P A Luciw; B M Peterlin
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

5.  RNA binding site of R17 coat protein.

Authors:  P J Romaniuk; P Lowary; H N Wu; G Stormo; O C Uhlenbeck
Journal:  Biochemistry       Date:  1987-03-24       Impact factor: 3.162

6.  Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1.

Authors:  M R Sadaie; T Benter; F Wong-Staal
Journal:  Science       Date:  1988-02-19       Impact factor: 47.728

7.  NusA protein is necessary and sufficient in vitro for phage lambda N gene product to suppress a rho-independent terminator placed downstream of nutL.

Authors:  W Whalen; B Ghosh; A Das
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  HIV-1 Tat protein trans-activates transcription in vitro.

Authors:  R A Marciniak; B J Calnan; A D Frankel; P A Sharp
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

9.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.

Authors:  S Roy; U Delling; C H Chen; C A Rosen; N Sonenberg
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

10.  The nusA gene protein of Escherichia coli. Its identification and a demonstration that it interacts with the gene N transcription anti-termination protein of bacteriophage lambda.

Authors:  J Greenblatt; J Li
Journal:  J Mol Biol       Date:  1981-03-25       Impact factor: 5.469

View more
  26 in total

1.  Molecular dynamics simulations on HIV-1 Tat.

Authors:  Sergio Pantano; Mudit Tyagi; Mauro Giacca; Paolo Carloni
Journal:  Eur Biophys J       Date:  2003-11-08       Impact factor: 1.733

2.  Comparative analysis of RNA/protein dynamics for the arginine-rich-binding motif and zinc-finger-binding motif proteins encoded by HIV-1.

Authors:  Hui Wang; Xiaojing Ma; Yu-Shan Yeh; Yongjin Zhu; Matthew D Daugherty; Alan D Frankel; Karin Musier-Forsyth; Paul F Barbara
Journal:  Biophys J       Date:  2010-11-17       Impact factor: 4.033

3.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1.

Authors:  R Taube; K Fujinaga; D Irwin; J Wimmer; M Geyer; B M Peterlin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 5.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

6.  In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus.

Authors:  J A Mikovits; P M Hoffman; A Rethwilm; F W Ruscetti
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

7.  NMR analysis of the trans-activation response (TAR) RNA element of equine infectious anemia virus.

Authors:  D W Hoffman; S W White
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

8.  Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.

Authors:  S J Madore; B R Cullen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Visna virus Tat protein: a potent transcription factor with both activator and suppressor domains.

Authors:  L M Carruth; J M Hardwick; B A Morse; J E Clements
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.